These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Where the money is. Fitzgerald M Nat Biotechnol; 2006 Mar; 24(3):240-2. PubMed ID: 16525370 [No Abstract] [Full Text] [Related]
5. The rise of European venture capital for biotechnology. Howell M; Trull M; Dibner MD Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356 [No Abstract] [Full Text] [Related]
6. VC funding hits high in Q1. Lawrence S Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825 [No Abstract] [Full Text] [Related]
7. Enthusiasm cools in Q2. Lawrence S Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352 [No Abstract] [Full Text] [Related]
8. Mixed results in Q1. Lawrence S Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059 [No Abstract] [Full Text] [Related]
9. IPOs break $1 billion in Q2. Lawrence S Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349 [No Abstract] [Full Text] [Related]
10. 2006: a stellar year for financing. Lawrence S Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738 [No Abstract] [Full Text] [Related]
11. Paying over the odds. Jacobs T Nat Biotechnol; 2006 Jan; 24(1):29. PubMed ID: 16404388 [No Abstract] [Full Text] [Related]
12. The protection racket. Jacobs T Nat Biotechnol; 2006 Sep; 24(9):1081. PubMed ID: 16964213 [No Abstract] [Full Text] [Related]
14. Korean biotechs seize opportunity to list on public markets. Louët S Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042 [No Abstract] [Full Text] [Related]
15. Public markets show signs of life. Mitchell P Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181 [No Abstract] [Full Text] [Related]
16. 2005: biotech partners up. Lawrence S Nat Biotechnol; 2006 Feb; 24(2):126. PubMed ID: 16465145 [No Abstract] [Full Text] [Related]